GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Taiwan Advance Bio-Pharmaceutical 4186.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

6.90

+2.68%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Taiwan Advance Bio-Pharmaceutical

Its shares trade on Taipei Exchange under the ticker 4186.TWO. It has been listed since 27 November 2012. In the fiscal year to 31 December 2025, it reported revenue of TWD 364.8m and net income of TWD 28.0m. At that date it held total assets of TWD 746.7m and shareholders' equity of TWD 285.1m.

Taiwan Advance Bio-Pharmaceutical, Inc. engages in the research, development, production, and sale of drug residue testing reagents. The company is headquartered in Taipei City, Taipei. The company went IPO on 2012-11-27. The firm is also involved in drug abuse testing business, the development and storage of cord blood stem cells, as well as the provision of biotechnology services. The firm operates its businesses in domestic market and overseas markets, such as the rest areas of Asia and Europe.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
27 Nov 2012
Employees
167

Leadership

Pay as last reported

  • Wenlong SuChairman of the Board, General Manager, Acting Deputy General Manager, since 2025
  • Yaocong ChenDeputy General Manager, Director
  • Liling ZhangHead of Finance and Accounting
  • Hongtian ChenDirector
  • Yulin ChenDirector
  • Jundian GaoDirector
  • Mr. Yuji LinDirector
  • Yaohua LuDirector
  • Difen WuDirector
  • Qiuxia FengIndependent Director
  • Mingqi FuIndependent Director
  • Xiuyuan ZhouIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company engages in the research and development of drug residue testing reagents.
  • Taiwan Advance Bio-Pharmaceutical operates in the domestic market and overseas markets in Asia.
  • The firm is involved in the development and storage of cord blood stem cells.

Weaknesses

  • The company has only 167 employees, which may limit operational scale significantly.
  • Taiwan Advance Bio-Pharmaceutical is headquartered in Taipei City, which might restrict local talent access.
  • The firm went public on 27 November 2012, indicating a relatively recent market entry.

Opportunities

  • The company can expand its drug abuse testing business into the European market.
  • Taiwan Advance Bio-Pharmaceutical can grow its biotechnology services in the rest of Asia.
  • The firm can leverage its cord blood stem cell storage for new health segments.

Threats

  • Competition in the biotechnology sector may reduce market share for drug residue reagents.
  • Economic downturns in Europe could decrease demand for overseas biotechnology services significantly.
  • Regulatory changes in Taiwan might impact the production of drug abuse testing products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.